Oscar Patterson-Lomba

Education

Ph.D., applied mathematics, Arizona State University; B.S., physics, Montclair State University

Summary of Experience

Dr. Patterson-Lomba has broad experience using mathematical epidemiology and statistical approaches to address a wide range of health care research challenges. His expertise includes comparative efficacy and safety, indirect mixed treatment comparisons, predictive analytics, and individualized medicine, as well as designing and implementing analytics platforms to enhance research capabilities. Dr. Patterson-Lomba has applied statistical methodologies to study clinical and economic outcomes in a broad range of disease areas (e.g., oncology, psychiatry, immunology, and ophthalmology) and data sources (e.g., clinical trials, medical claims, and surveys). His research has also involved analyzing complex contagion models to better understand the spread of infectious diseases in human populations, as well as the effectiveness of treatment strategies. Prior to joining Analysis Group, Dr. Patterson-Lomba was a postdoctoral fellow in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health.

Selected Publishing

• Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis

  Journal of Comparative Effectiveness Research, 2020
  2020

  Swallow E, Patterson-Lomba O, Yin L, Mehta R, Pelletier C, Kao D, Sheffield JK, Stonehouse T, Signorovitch J

  HEOR, Epidemiology & Market Access
• Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis

  Journal of Comparative Effectiveness Research, 2020
  2020

  Swallow E, Patterson-Lomba O, Ayyagari R, Pelletier C, Mehta R, Signorovitch J

  HEOR, Epidemiology & Market Access
• Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer

  Breast Journal, 2019
  2019

  Patterson-Lomba O, Dalal AA, Ayyagari R, Liu O, Dervishi E, Platt E, Chandiwana D, O'Shaughnessy JA

  HEOR, Epidemiology & Market Access
• Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis

  BMC Neurology, 2019
  2019

  Patterson-Lomba O, Ayyagari R, Carroll B

  HEOR, Epidemiology & Market Access
• Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer

  Current Oncology, 2019
  2019

  Levy BP, J E Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Parisi M

  HEOR, Epidemiology & Market Access
• Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer: A Network Meta-analysis

  Clinical Therapeutics. Apr 2018;40(4):628-639 e623
  2018

  Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA

• Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States

  2018 Oct;35(10):1564-1577
  2018

  Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL

  HEOR, Epidemiology & Market Access
• Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis

  Current Medical Research and Opinion. 2018 Sep;34(9):1645-1652 
  2018

  Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA

  HEOR, Epidemiology & Market Access

News

• January 25, 2021

  Research by Analysis Group Consultants Is Among the Most Downloaded Articles in the Journal of Comparative Effectiveness Research

  HEOR, Epidemiology & Market Access